Opinion

Video

Gene Therapy for Treatment of Duchenne Muscular Dystrophy

Focusing on gene therapy and exon skipping medications, an expert on Duchenne muscular dystrophy discusses current and emerging treatment options.

Video content above is prompted by the following questions:

  • Provide an overview of delandistrogene moxeparvovec, micro-dystrophin gene therapy, that received accelerated approval for Duchenne muscular dystrophy (DMD) in 2023.
  • Discuss ongoing studies for fordadistrogene movaparvovec gene therapy and other exon skipping therapies.
Related Videos
Michael Levy, MD, PhD, is featured in this series.
Michael Levy, MD, PhD, is featured in this series.
Michael Levy, MD, PhD, is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.